Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Green light for 10 new medicines in November 2025

Written by | 7 Dec 2025

The European Medicines Agency’s key committee on human medicines (CHMP) recommended ten medicines for approval at its November 2025 meeting. This brings to 97 the total number of… read more.

Positive CHMP opinion for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for pneumococcal vaccination in adults – Merck

Written by | 4 Aug 2025

Merck Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA recommended the approval of Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for active immunization… read more.

EMA approves 17 medicines at December meeting

Written by | 28 Dec 2024

The European Medicines Agency rounded off a busy year by approving seventeen new medicines. At its December meeting, the Committee for Medicinal Products for Human Use (CHMP) also… read more.

CHMP positive for Flucelvax vaccine to prevent influenza

Written by | 24 Oct 2024

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Flucelvax, intended for the prevention of influenza… read more.

EU gives green light for 14 new medicines

Written by | 5 Sep 2024

The European Medicines Agency (EMA) has approved fourteen new medicines at a summer meeting, with a further eleven products recommended for extension of therapeutic indications. The Agency’s human… read more.

EU green light for 10 new medicines – extends the scope of 11 existing products

Written by | 8 Jul 2024

The European Medicines Agency (EMA) has recommended ten new products for approval at a bumper June meeting which also saw therapeutic extensions granted for eleven drugs. The watchdog’s… read more.

CHMP positive recommendation to change the marketing authorisation for Rozlytrek (entrectinib) – Roche

Written by | 2 May 2024

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for… read more.

Green light for 12 new medicines from EU watchdog

Written by | 8 Apr 2024

The European Medicines Agency (EMA) has recommended the approval of twelve new products, following reviews by its key human medicines committee (CHMP). This brings to twenty-five the number… read more.

Green light for 77 new medicines in the EU in 2023

Written by | 11 Jan 2024

A total of seventy-seven new medicinal products were approved in Europe last year, seven of which were given the green light in December. At European level, the EMA’s… read more.

EU gives green light for 7 new medicines

Written by | 23 Oct 2023

The European Medicines Agency (EMA) has recommended seven medicines for approval at its October 2023 meeting. The brings the total number of newly approved medicines this year to… read more.

CHMP recommends Abrysvo the first RSV vaccine to protect infants up to 6 months of age and older adults – Pfizer

Written by | 31 Jul 2023

The CHMP has recommended granting a marketing authorization for Pfizer’s Abrysvo (bivalent, recombinant), a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is… read more.

CHMP recommends Lyfnua as a treatment for refractory or unexplained chronic cough – Merck Inc

Written by | 25 Jul 2023

Merck Inc., known as MSD outside the United States and Canada, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.